$TTOO
T2 Biosystems, Inc.

2019 Q2 Form 10-Q Financial Statement

#000156459019018534 Filed on May 10, 2019

View on sec.gov

Income Statement

Concept 2019 Q2 2019 Q1 2018 Q1
Revenue $1.804M $1.785M $2.311M
YoY Change -54.11% -22.76% 145.59%
Cost Of Revenue $4.820M $4.390M $3.273M
YoY Change 39.31% 34.13% 101.17%
Gross Profit -$3.020M -$2.600M -$962.0K
YoY Change -742.55% 170.27% 40.23%
Gross Profit Margin -167.41% -145.66% -41.63%
Selling, General & Admin $6.722M $7.055M $5.755M
YoY Change -11.68% 22.59% -2.03%
% of Gross Profit
Research & Development $4.048M $3.901M $4.718M
YoY Change 7.98% -17.32% -28.35%
% of Gross Profit
Depreciation & Amortization $600.0K $600.0K $629.0K
YoY Change 0.0% -4.61% -9.37%
% of Gross Profit
Operating Expenses $10.77M $10.96M $10.47M
YoY Change -5.19% 4.61% -15.94%
Operating Profit -$13.79M -$13.56M -$11.44M
YoY Change 26.63% 18.57% -13.01%
Interest Expense -$2.000M -$1.782M -$1.568M
YoY Change 32.45% 13.65% -4.22%
% of Operating Profit
Other Income/Expense, Net $140.0K $194.0K $90.00K
YoY Change 102.9% 115.56% 13.92%
Pretax Income -$15.65M -$15.15M -$12.91M
YoY Change 27.03% 17.35% -12.18%
Income Tax
% Of Pretax Income
Net Earnings -$15.65M -$15.15M -$12.91M
YoY Change 26.96% 17.3% -12.17%
Net Earnings / Revenue -867.35% -848.57% -558.76%
Basic Earnings Per Share
Diluted Earnings Per Share -$352.2K -$342.1K -$358.8K
COMMON SHARES
Basic Shares Outstanding 44.34M 44.32M 36.02M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q2 2019 Q1 2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $28.42M $37.40M $29.73M
YoY Change -59.81% 25.8% -49.46%
Cash & Equivalents $28.42M $37.40M $29.73M
Short-Term Investments
Other Short-Term Assets $710.0K $1.740M $630.0K
YoY Change -17.44% 176.19% -32.26%
Inventory $3.100M $2.664M $2.082M
Prepaid Expenses
Receivables $1.179M $1.773M $582.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $33.41M $43.58M $33.02M
YoY Change -55.64% 31.96% -45.55%
LONG-TERM ASSETS
Property, Plant & Equipment $7.262M $7.128M $8.710M
YoY Change -14.56% -18.16% -39.8%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $206.0K $206.0K $206.0K
YoY Change -47.18% 0.0% -26.43%
Total Long-Term Assets $11.76M $11.98M $9.096M
YoY Change 32.39% 31.67% -39.39%
TOTAL ASSETS
Total Short-Term Assets $33.41M $43.58M $33.02M
Total Long-Term Assets $11.76M $11.98M $9.096M
Total Assets $45.17M $55.56M $42.12M
YoY Change -46.36% 31.9% -44.33%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.911M $618.0K $779.0K
YoY Change 153.13% -20.67% -32.9%
Accrued Expenses $8.823M $7.784M $5.606M
YoY Change 109.57% 38.85% 38.08%
Deferred Revenue $677.0K $658.0K
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $42.89M $42.45M $41.30M
YoY Change 1037.67% 2.78% 3028.79%
Total Short-Term Liabilities $57.80M $53.74M $50.92M
YoY Change 460.34% 5.52% 471.32%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $610.0K
YoY Change -100.0% -100.0% -98.47%
Other Long-Term Liabilities $2.990M $3.400M $680.0K
YoY Change 210.81% 400.0% 288.57%
Total Long-Term Liabilities $2.990M $3.400M $1.290M
YoY Change 210.81% 163.57% 637.14%
TOTAL LIABILITIES
Total Short-Term Liabilities $57.80M $53.74M $50.92M
Total Long-Term Liabilities $2.990M $3.400M $1.290M
Total Liabilities $60.79M $57.14M $52.21M
YoY Change 439.06% 9.44% 474.49%
SHAREHOLDERS EQUITY
Retained Earnings -$348.0M -$332.3M -$278.9M
YoY Change 19.47% 19.14% 27.72%
Common Stock $332.3M $330.7M $268.8M
YoY Change 2.82% 23.02% 9.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$15.62M -$1.580M -$10.09M
YoY Change
Total Liabilities & Shareholders Equity $45.17M $55.56M $42.12M
YoY Change -46.36% 31.9% -44.33%

Cashflow Statement

Concept 2019 Q2 2019 Q1 2018 Q1
OPERATING ACTIVITIES
Net Income -$15.65M -$15.15M -$12.91M
YoY Change 26.96% 17.3% -12.17%
Depreciation, Depletion And Amortization $600.0K $600.0K $629.0K
YoY Change 0.0% -4.61% -9.37%
Cash From Operating Activities -$8.840M -$12.87M -$11.74M
YoY Change 2.55% 9.58% -7.96%
INVESTING ACTIVITIES
Capital Expenditures -$250.0K $194.0K $56.00K
YoY Change -53.7% 246.43% -96.49%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$250.0K -$194.0K -$56.00K
YoY Change -53.7% 246.43% -96.49%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 110.0K -344.0K -348.0K
YoY Change -99.78% -1.15% 10.83%
NET CHANGE
Cash From Operating Activities -8.840M -12.87M -11.74M
Cash From Investing Activities -250.0K -194.0K -56.00K
Cash From Financing Activities 110.0K -344.0K -348.0K
Net Change In Cash -8.980M -13.41M -12.15M
YoY Change -121.91% 10.37% -17.18%
FREE CASH FLOW
Cash From Operating Activities -$8.840M -$12.87M -$11.74M
Capital Expenditures -$250.0K $194.0K $56.00K
Free Cash Flow -$8.590M -$13.06M -$11.80M
YoY Change 6.31% 10.71% -17.8%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1773000
CY2019Q1 us-gaap Assets Current
AssetsCurrent
43578000
CY2019Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7128000
CY2019Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
180000
CY2019Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
44339243
CY2019Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
37400000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
50805000
CY2018Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1786000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
56608000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7315000
CY2019Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2019Q1 us-gaap Inventory Net
InventoryNet
2664000
CY2019Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
330694000
CY2019Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-332318000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
-1580000
CY2019Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
55555000
CY2019Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Inventory Net
InventoryNet
2677000
CY2019Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1741000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1340000
CY2019Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4463000
CY2019Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
618000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
744000
CY2019Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7784000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6073000
CY2019Q1 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
2225000
CY2019Q1 us-gaap Notes Payable Current
NotesPayableCurrent
42450000
CY2018Q4 us-gaap Notes Payable Current
NotesPayableCurrent
42373000
CY2019Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
44339243
CY2019Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
44339243
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
800000
CY2018Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
133000
CY2019Q1 us-gaap Assets
Assets
55555000
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
44175441
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
44175441
CY2019Q1 us-gaap Liabilities Current
LiabilitiesCurrent
53735000
CY2019Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
42059000
CY2018Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
180000
CY2019Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
206000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
206000
CY2018Q4 us-gaap Assets
Assets
64309000
CY2018Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
268000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
52297000
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
328514000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-317171000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
11387000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
64309000
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
2142000
CY2019Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
658000
CY2018Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
697000
CY2018Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
492000
CY2019Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3259000
CY2019Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
141000
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q1 us-gaap Common Stock Value
CommonStockValue
44000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
44000
CY2019Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1785000
CY2018Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2311000
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3901000
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4718000
CY2019Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7055000
CY2018Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
5755000
CY2019Q1 us-gaap Costs And Expenses
CostsAndExpenses
15344000
CY2018Q1 us-gaap Costs And Expenses
CostsAndExpenses
13746000
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-13559000
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-11435000
CY2019Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-1782000
CY2018Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-1568000
CY2019Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
194000
CY2018Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
90000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-15147000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-12913000
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.34
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.36
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
44282345
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35978306
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
1340000
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1381000
CY2018Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
5000
CY2018Q1 us-gaap Cumulative Effect On Retained Earnings Net Of Tax1
CumulativeEffectOnRetainedEarningsNetOfTax1
100000
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
-10087000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
147000
CY2019Q1 us-gaap Profit Loss
ProfitLoss
-15147000
CY2018Q1 us-gaap Profit Loss
ProfitLoss
-12913000
CY2019Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
557000
CY2018Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
629000
CY2019Q1 ttoo Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
342000
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2033000
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1381000
CY2019Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-83000
CY2019Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
568000
CY2018Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
560000
CY2018Q1 us-gaap Straight Line Rent
StraightLineRent
52000
CY2019Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-13000
CY2018Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
115000
CY2019Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
401000
CY2018Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-145000
CY2019Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
141000
CY2018Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-64000
CY2019Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-126000
CY2018Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
132000
CY2019Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
118000
CY2018Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-682000
CY2019Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-31000
CY2018Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-749000
CY2019Q1 ttoo Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-735000
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12867000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-13405000
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-12146000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
50985000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
37580000
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11742000
CY2019Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
194000
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
29913000
CY2018Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
56000
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-194000
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-56000
CY2018Q1 ttoo Proceeds From Issuance Of Common Stock And Stock Options Exercised
ProceedsFromIssuanceOfCommonStockAndStockOptionsExercised
4000
CY2019Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
344000
CY2018Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
352000
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-344000
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-348000
CY2019Q1 us-gaap Interest Paid Net
InterestPaidNet
1131000
CY2018Q1 us-gaap Interest Paid Net
InterestPaidNet
972000
CY2019Q1 ttoo Transfer Of T2 Owned Instruments And Components To From Inventory
TransferOfT2OwnedInstrumentsAndComponentsToFromInventory
-154000
CY2018Q1 ttoo Transfer Of T2 Owned Instruments And Components To From Inventory
TransferOfT2OwnedInstrumentsAndComponentsToFromInventory
802000
CY2019Q1 ttoo Change In Fair Value Of Warrants Issued Upon Modification
ChangeInFairValueOfWarrantsIssuedUponModification
147000
CY2019Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4805000
CY2019Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
56000
CY2018Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
119000
CY2019Q1 us-gaap Nature Of Operations
NatureOfOperations
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Nature of Business </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">T2 Biosystems, Inc. (the &#8220;Company&#8221;) was incorporated on April&#160;27, 2006 as a Delaware corporation with operations based in Lexington, Massachusetts. The Company is an&#160;<font style="font-style:italic;">in vitro</font>&#160;diagnostics company that has developed an innovative and proprietary technology platform that offers a rapid, sensitive and simple alternative to existing diagnostic methodologies. The Company is using its T2 Magnetic Resonance technology (&#8220;T2MR&#8221;) to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as low as one colony forming unit per milliliter (&#8220;CFU/mL&#8221;). The Company&#8217;s initial development efforts target sepsis and Lyme disease, which are areas of significant unmet medical need in which existing therapies could be more effective with improved diagnostics. On September&#160;22, 2014, the Company received market clearance from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) for its first two products, the T2Dx Instrument (the &#8220;T2Dx&#8221;) and T2Candida Panel (&#8220;T2Candida&#8221;). On May 24, 2018, the Company received market clearance from the FDA for its T2Bacteria Panel (&#8220;T2Bacteria&#8221;). </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has devoted substantially all of its efforts to research and development, business planning, recruiting management and technical staff, acquiring operating assets, raising capital, and, most recently, the commercialization and improvement of its existing products.</p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liquidity and Going Concern </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At March&#160;31, 2019, the Company had cash and cash equivalents of $37.4 million and an accumulated deficit of $332.3 million. The future success of the Company is dependent on its ability to successfully commercialize its products, obtain regulatory clearance for and successfully launch its future product candidates, obtain additional capital and ultimately attain profitable operations. Historically, the Company has funded its operations primarily through its August 2014 initial public offering, its December 2015 public offering, its September 2016 private investment in public equity (&#8220;PIPE&#8221;) financing, its September 2017 public offering, its June 2018 public offering, private placements of redeemable convertible preferred stock and debt financing arrangements.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to a number of risks similar to other newly commercial life science companies, including, but not limited to commercially launching the Company&#8217;s products, development and market acceptance of the Company&#8217;s product candidates, development by its competitors of new technological innovations, protection of proprietary technology, and raising additional capital. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Having obtained authorization from the FDA to market the T2Dx, T2Candida, and T2Bacteria, the Company has incurred significant commercialization expenses related to product sales, marketing, manufacturing and distribution. The Company may seek to fund its operations through public equity, private equity or debt financings, as well as other sources. However, the Company may be unable to raise additional funds or enter into such other arrangements when needed, on favorable terms, or at all. The Company&#8217;s failure to raise capital or enter into such other arrangements if and when needed would have a negative impact on the Company&#8217;s business, results of operations, financial condition and the Company&#8217;s ability to develop and commercialize T2Dx, T2Candida, T2Bacteria and other product candidates. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of Accounting Standards Codification (&#8220;ASC&#8221;) 205-40,&#160;<font style="font-style:italic;">Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern</font>, management must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of management&#8217;s plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company&#8217;s ability to continue as a going concern. The mitigating effect of management&#8217;s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management believes that its existing cash and cash equivalents at March&#160;31, 2019 will be sufficient to allow the Company to fund its current operating plan through May 2020. However, as certain elements of the Company&#8217;s operating plan are outside of the Company&#8217;s control, including the receipt of certain development and regulatory milestone payments under the Company&#8217;s Co-Development agreements, they cannot be considered probable. Under ASC 205-40, the future receipt of potential funding from the Company&#8217;s Co-Development partners and other resources cannot be considered probable at this time because none of the plans are entirely within the Company&#8217;s control. In addition, the Company is required to maintain a minimum cash balance under its Term Loan Agreement with CRG Servicing LLC (&#8220;CRG&#8221;) (Note 6).<font style="color:#000000;"> </font></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These conditions raise substantial doubt regarding the Company&#8217;s ability to continue as a going concern for a period of one year after the date that the financial statements are issued. Management's plans to alleviate the conditions that raise substantial doubt include raising additional funding, earning milestone payments pursuant the Company&#8217;s Co- Development agreements, delaying certain research projects and capital expenditures and eliminating certain future operating expenses in order to fund operations at reduced levels for the Company to continue as a going concern for a period of twelve months from the date the financial statements are issued.&nbsp;&nbsp;Management has concluded the likelihood that its plan to obtain sufficient funding from one or more of these sources or adequately reduce expenditures will be successful, while reasonably possible, is less than probable.&nbsp;&nbsp;Accordingly, the Company has concluded that substantial doubt exists about the Company&#8217;s ability to continue as a going concern for a period of at least twelve months from the date of issuance of these condensed consolidated financial statements.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.<font style="color:#000000;"> </font></p>
CY2019Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
600000
CY2018Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
600000
CY2018 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
100000
CY2019Q1 us-gaap Capitalized Contract Cost Gross
CapitalizedContractCostGross
0
CY2019Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
847000
CY2019Q1 us-gaap Guarantees Indemnifications And Warranties Policies
GuaranteesIndemnificationsAndWarrantiesPolicies
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Guarantees </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As permitted under Delaware law, the Company indemnifies its officers and directors for certain events or occurrences while each such officer or director is, or was, serving at the Company&#8217;s request in such capacity. The term of the indemnification is the officer&#8217;s or director&#8217;s lifetime. The maximum potential amount of future payments the Company could be required to make is unlimited; however, the Company has directors&#8217; and officers&#8217; liability insurance coverage that limits its exposure and enables the Company to recover a portion of any future amounts paid. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company leases office, laboratory and manufacturing space under noncancelable operating leases. The Company has standard indemnification arrangements under the leases that require it to indemnify the landlords against all costs, expenses, fines, suits, claims, demands, liabilities, and actions directly resulting from any breach, violation or nonperformance of any covenant or condition of the Company&#8217;s leases. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the ordinary course of business, the Company enters into indemnification agreements with certain suppliers and business partners where the Company has certain indemnification obligations limited to the costs, expenses, fines, suits, claims, demands, liabilities and actions directly resulting from the Company&#8217;s gross negligence or willful misconduct, and in certain instances, breaches, violations or nonperformance of covenants or conditions under the agreements. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March&#160;31, 2019 and December&#160;31, 2018, the Company had not experienced any material losses related to these indemnification obligations, and no material claims with respect thereto were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established. </p>
CY2019Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2019Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
3600000
CY2019Q1 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Explanation
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionExplanation
The Company expects to recognize revenue on the remaining performance obligations over the next 2 years.
CY2019Q1 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
100000
CY2018Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0
CY2018Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
639000
CY2019Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
1630000
CY2018Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
1713000
CY2019Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
187000
CY2018Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
325000
CY2019Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
18971000
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
18622000
CY2019Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
11843000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
11307000
CY2019Q1 us-gaap Inventory Work In Process And Raw Materials
InventoryWorkInProcessAndRawMaterials
600000
CY2018Q4 us-gaap Inventory Work In Process And Raw Materials
InventoryWorkInProcessAndRawMaterials
300000
CY2019Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2815000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2940000
CY2019Q1 ttoo Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
272000
CY2018Q4 ttoo Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
359000
CY2019Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
485000
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
576000
CY2019Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1900000
CY2019Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2312000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2198000
CY2019Q1 ttoo Transfer Of Liabilities To Accrued Expenses And Other Current Liabilities
TransferOfLiabilitiesToAccruedExpensesAndOtherCurrentLiabilities
1600000
CY2018 ttoo Transfer Of Liabilities To Accrued Expenses And Other Current Liabilities
TransferOfLiabilitiesToAccruedExpensesAndOtherCurrentLiabilities
1400000
CY2019Q1 us-gaap Notes Payable
NotesPayable
42450000
CY2018Q4 us-gaap Notes Payable
NotesPayable
42373000
CY2019Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1000000
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1920000
CY2018Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1357000
CY2019Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7277476
CY2018Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6785503
CY2019Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
116000
CY2019Q1 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
27000
CY2019Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
499000
CY2019Q1 us-gaap Variable Lease Cost
VariableLeaseCost
172000
CY2019Q1 us-gaap Lease Cost
LeaseCost
814000
CY2019Q1 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P2M12D
CY2019Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y7M6D
CY2019Q1 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.145
CY2019Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.119
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1697000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2313000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1951000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
23000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
5984000
CY2019Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
825000
CY2019Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
5159000
CY2019Q1 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
618000
CY2019Q1 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
618000
CY2019Q1 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
9000
CY2019Q1 us-gaap Finance Lease Liability
FinanceLeaseLiability
609000
CY2019Q1 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
ttoo:OperatingLeaseAssetsMember
CY2019Q1 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
879000
CY2019Q1 us-gaap Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
ttoo:PropertyAndEquipmentMember
CY2019Q1 ttoo Operating And Finance Lease Assets
OperatingAndFinanceLeaseAssets
5342000
CY2019Q1 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
ttoo:AccruedExpensesAndOtherCurrentLiabilitiesMember
CY2019Q1 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
609000
CY2019Q1 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
ttoo:NotesPayableMember
CY2019Q1 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
ttoo:NoncurrentOperatingLeaseLiabilitiesMember
CY2019Q1 us-gaap Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
ttoo:NotesPayableNetOfCurrentPortionMember
CY2019Q1 ttoo Operating And Finance Lease Liabilities
OperatingAndFinanceLeaseLiabilities
5768000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
2225000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
2277000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
1926000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
6428000
CY2018 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
2000000
CY2017 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
1900000
us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
84678
CY2019Q1 ttoo Royalty On Net Sales Sublicensing Gross Revenue
RoyaltyOnNetSalesSublicensingGrossRevenue
0.10

Files In Submission

Name View Source Status
0001564590-19-018534-index-headers.html Edgar Link pending
0001564590-19-018534-index.html Edgar Link pending
0001564590-19-018534.txt Edgar Link pending
0001564590-19-018534-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ttoo-10q_20190331.htm Edgar Link pending
ttoo-20190331.xml Edgar Link completed
ttoo-20190331.xsd Edgar Link pending
ttoo-20190331_cal.xml Edgar Link unprocessable
ttoo-20190331_def.xml Edgar Link unprocessable
ttoo-20190331_lab.xml Edgar Link unprocessable
ttoo-20190331_pre.xml Edgar Link unprocessable
ttoo-ex101_250.htm Edgar Link pending
ttoo-ex102_251.htm Edgar Link pending
ttoo-ex311_7.htm Edgar Link pending
ttoo-ex312_8.htm Edgar Link pending
ttoo-ex321_6.htm Edgar Link pending
ttoo-ex322_9.htm Edgar Link pending